Category Archives: Recent News

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients ...

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 ...

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. TORONTO, ...

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT(TM) in High-Risk Early-Stage Triple Negative Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders

August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement. ...

BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting

Shareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including ...

BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS(TM) Immunotherapy for Cancer

NCI award (non-dilutive grant) further validates novel personalized off-the-shelf immunotherapy approach; and may facilitate future ...

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia, May ...

BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...